Observation vs. targeted high-dose radiation for metastatic prostate cancer

What The Study Did:

This randomized clinical trial compared how effectively high-dose, targeted radiation therapy versus no treatment (observation) among 54 men prevented the progression over six months of recurrent hormone-sensitive prostate cancer that has metastasized to a small number of sites in the body.

Authors:

Phuoc T. Tran, M.D., Ph.D., of the Johns Hopkins University School of Medicine in Baltimore, is the corresponding author.

To access the embargoed study:

Visit our For The Media website at this link

https:/

/

media.

jamanetwork.

com/

(doi:10.1001/jamaoncol.2020.0147)

Editor’s Note:

The article includes conflict of interest and funding/support disclosures. Please see the articles for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

###

Media advisory:

The full study and commentary are linked to this news release. A visual abstract is below.

Embed this link to provide your readers free access to the full-text article

This link will be live at the embargo time

https:/

/

jamanetwork.

com/

journals/

jamaoncology/

fullarticle/

10.

1001/

jamaoncol.

2020.

0147?guestAccessKey=

e5501192-c562-4e38-9167-81da44e28982&utm_source=

For_The_Media&utm_medium=

referral&utm_campaign=

ftm_links&utm_content=

tfl&utm_term=

032620